 Home > Active Ingredient News > Antitumor Therapy > Aliment Pharmacol Ther: Serum GDF15 can predict the risk of liver cancer after hepatitis C virus is eliminated

Aliment Pharmacol Ther: Serum GDF15 can predict the risk of liver cancer after hepatitis C virus is eliminated

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

fda process validation

adar 2 15

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The treatment of hepatitis C has changed dramatically due to the introduction of direct-acting antiviral drugs (DAAs).
Almost all patients with chronic hepatitis C (CH-C) can be completely cured by DAA
.

However, due to the risk of hepatocellular carcinoma (HCC), after the hepatitis C virus (HCV) is cleared, patients should continue to be followed up

Due to the risk of hepatocellular carcinoma (HCC), patients should continue to be followed up after hepatitis C virus (HCV) has been cleared

This study aims to evaluate the predictive value of GDF15 on the risk of HCC after HCV is eliminated

The researchers tested the GDF15 levels in the serum of chronic HCV- infected patients who had received a sustained virological response through DAA treatment without a history of HCC
.

1606 patients were randomly divided into two cohorts: the derivative cohort (n=964) and the verification cohort (n=642)

Infect

The risk of HCC in patients stratified by GDF15, AFP and FIB-4 in the derived cohort

In the derivative cohort, the serum GDF15 level of patients who developed HCC after DAA treatment was chronically higher than that of patients without HCC
.

Multivariate Cox proportional hazard analysis showed that baseline GDF15 (>1350 pg/mL, HR 2.

Baseline GDF15 (>1350 pg/mL, HR 2.

Validation cohort, the risk of HCC in patients stratified according to the total score

Based on GDF15, AFP and FIB-4 index scores, the risk of HCC occurrence was stratified
.

In the validation cohort, the three-year cumulative incidence of HCC in the low-scoring group (n=171), medium-scoring group (n=300), and high-scoring group (n=166) were 0.

In summary, serum GDF15 can predict the occurrence of primary liver cancer
.

The GDF15, AFP and FIB-4 index scores can predict the risk of liver cancer after hepatitis C is cured

Original source:

Myojin Yuta,Hikita Hayato,Tahata Yuki et al.

Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.